Biologic versus anatomic resectability criteria in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Review question: In adults with potentially operable PDAC, do biologic or combined biologic-anatomic resectability criteria predict survival and surgical outcomes better than anatomy-only criteria? Is this a good, feasible meta-analysis focused topic to publish on. Do your research extensively and look out for any similar publications.
"pancreatic ductal adenocarcinoma" AND "biologic resectability" AND "anatomic"
"pancreatic cancer" AND "resectability criteria" AND "CA 19-9" AND "survival"
biologic resectability criteria pancreatic ductal adenocarcinoma systematic review meta-analysis 2024 2025 2026
"pancreatic cancer" AND "biologic" AND "borderline resectable" AND "CA 19-9" AND "neoadjuvant"
"pancreatic cancer" AND "resectability" AND "biological criteria" AND "survival"
"pancreatic cancer" AND "resectability" AND "biological" AND "NCCN" AND "outcomes"
"pancreatic cancer" AND "ABC criteria" AND "resectability" AND "JSHBPS"
"pancreatic cancer" AND "biologic" AND "resectability" AND "Oba" OR "JSHBPS" AND "criteria"
"pancreatic cancer" AND "upfront resection" AND "CA 19-9" AND "futile" AND "neoadjuvant"
JSHBPS biologic resectability pancreatic cancer Oba systematic review meta-analysis 2024 2025 PubMed
"pancreatic cancer" AND "resectable" AND "futility" AND "upfront surgery" AND "CA 19-9"
"biologic resectability" OR "biological resectability" pancreatic cancer meta-analysis systematic review published 2023 2024 2025
Create a PROSPERO protocol template tailored for this SR/MA
Create a PROSPERO protocol template tailored for this SR/MA
PROSPERO registration form fields 2024 2025 systematic review template required sections
PDAC Biologic vs Anatomic Resectability PROSPERO Protocol v1.0
Word Document · DOCX
What's inside the document
| Section | Content |
|---|---|
| Title Page | Full title, version, date, 5-author review team table with ORCID fields, COI and funding placeholders |
| 1 - Administrative | PROSPERO-ready title, keywords, milestone timeline table, stage of review at registration |
| 2 - Background | Clinical rationale; anatomy-only limitations; emergence of biologic criteria (JSHBPS BR-B, ABC/TAPS, Crippa futility data); gap justification; confirmation of no prior SR/MA |
| 3 - PICO | Primary + 5 secondary review questions; full PICO table with precise definitions for P, I, C, O, and Study design |
| 4 - Eligibility | Detailed inclusion (population, intervention, comparator, outcomes, design, language) and exclusion criteria table |
| 5 - Outcomes | Primary outcomes (OS and R0 rate) and 8 secondary outcomes in structured tables with data definitions |
| 6 - Search Strategy | 6 databases; additional sources (ClinicalTrials.gov, grey literature, citation searches); full 19-step MEDLINE/PubMed search string |
| 7 - Screening | Phase 1 (title/abstract) and Phase 2 (full-text) dual-reviewer process; kappa calibration; PRISMA flow diagram plan |
| 8 - Data Extraction | Standardised extraction items across 4 domains (study ID, population, biologic criteria, outcomes); missing data handling |
| 9 - Risk of Bias | RoB 2.0 (RCTs); ROBINS-I (observational); PROBAST (prognostic accuracy); NOS supplementary; overlapping cohort policy |
| 10 - Statistical Analysis | Random-effects model; effect measures by outcome type; heterogeneity (I², Q, Tau²); 8 pre-specified subgroup analyses; 6 sensitivity analyses; meta-regression for CA 19-9 threshold dose-response; publication bias; R software |
| 11 - GRADE | Certainty of evidence framework; upgrading/downgrading criteria; Summary of Findings table plan |
| 12 - Reporting | PRISMA 2020, PRISMA-P, MOOSE, GRADE, SWiM; amendment policy; target journal list |
| 13 - PROSPERO Fields | Copy-paste guide for all 28 PROSPERO registry fields - ready to enter online |
| 14 - References | 14 key references with full citations including PMIDs and DOIs |
| 15 - PRISMA-P Checklist | All 27 PRISMA-P 2015 items mapped to protocol sections |
- Fill in author names, affiliations, and ORCID IDs on the title page
- Specify the CA 19-9 threshold subgroup values in Section 10.3 if you have institutional preferences
- Check PROSPERO for any competing registrations at crd.york.ac.uk/prospero
- Submit to PROSPERO - use Section 13 as your field-by-field copy-paste guide
Generate a pilot data extraction form (Excel/REDCap template)